Neuroscience

Unlocking the Genius of Autism -New School Opens in Riverhead

Friday, June 11, 2021 - 1:32pm

RIVERHEAD, N.Y., June 11, 2021 /PRNewswire/ --Acton Academy Eastern Long Island today announced the first phase of the Autism Studio launching July 6, 2021 in Riverhead, NY.

Key Points: 
  • RIVERHEAD, N.Y., June 11, 2021 /PRNewswire/ --Acton Academy Eastern Long Island today announced the first phase of the Autism Studio launching July 6, 2021 in Riverhead, NY.
  • It is a revolutionary new program that seeks to unlock this highly intelligent, grossly misunderstood population.
  • The Autism Studio, phase one, will begin this July, inviting non-speaking and minimally-speaking autistic individuals to learn S2C.
  • Andrea has published two books on autism, Autism A New Humanity (Hay House 2015) and Autism: A New Perspective (KDP 2019) which she co-authored with a non-verbal autist from Portugal.

Bright Minds Biosciences to Present at the H.C. Wainwright Virtual Conference Psychedelics in Psychiatry and Beyond

Friday, June 11, 2021 - 1:00pm

The presentation will be webcast beginning at the aforementioned time and available for 7 days thereafter using the link provided above.

Key Points: 
  • The presentation will be webcast beginning at the aforementioned time and available for 7 days thereafter using the link provided above.
  • Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain.
  • Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors.
  • Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.

Spero Health Responds to High Rate of Drug Overdose Deaths With New Clinic in Cambridge

Friday, June 11, 2021 - 11:56am

Responding directly to this urgent need, Spero Health, a national leader in providing care for individuals struggling with substance use disorders announced it will open a new clinic in Cambridge, OH.

Key Points: 
  • Responding directly to this urgent need, Spero Health, a national leader in providing care for individuals struggling with substance use disorders announced it will open a new clinic in Cambridge, OH.
  • Spero Health has a growing network of over 55 clinics throughout Kentucky, Ohio, Tennessee, Virginia and Indiana, providing care for more than 9,000 patients.
  • As these deaths continue to increase, Spero Health remains committed to bringing lifesaving treatment to areas most in need with continued plans to expand rapidly throughout 2021.
  • It inflamed already out of control public health crises drug addiction and drug overdose deaths.

Medtronic Announces FDA Approval of its Next Generation Recharge-Free Spinal Cord Stimulation Platform

Thursday, June 10, 2021 - 2:00pm

Medtronic is continually innovating to advance spinal cord stimulation therapy technologies that improve quality of life for people with chronic pain.

Key Points: 
  • Medtronic is continually innovating to advance spinal cord stimulation therapy technologies that improve quality of life for people with chronic pain.
  • The Vanta neurostimulator represents a 10% increase in longevity compared to PrimeAdvanced, Medtronic's previous generation recharge-free device.
  • DTM SCS is currently available on the rechargeable Intellis SCS platform, and the company expects to share more information about its availability across the entire Medtronic spinal cord stimulator portfolio later this summer.
  • The rate of magnetic resonance imaging in patients with spinal cord stimulation.

DGAP-News: Axon Neuroscience to Present at 2021 BIO Digital

Thursday, June 10, 2021 - 12:06pm

NEW YORK, NY / ACCESSWIRE / June 10, 2021 / AXON NEUROSCIENCE SE & AXON COVIDAX a. s. (together "Axon"), clinical stage biotech company in the field of Alzheimer's disease with first-in-man tau vaccine AADvac1 announced today that it will deliver a company presentation at the biotech event BIO Digital scheduled June 10-11 & 14-18, 2021.

Key Points: 
  • NEW YORK, NY / ACCESSWIRE / June 10, 2021 / AXON NEUROSCIENCE SE & AXON COVIDAX a. s. (together "Axon"), clinical stage biotech company in the field of Alzheimer's disease with first-in-man tau vaccine AADvac1 announced today that it will deliver a company presentation at the biotech event BIO Digital scheduled June 10-11 & 14-18, 2021.
  • Michal Fresser, CEO of Axon Neuroscience: "We are delighted to be able to present our COVID-19 program at BIO Digital.
  • Attendees at BIO Digital will be able to view Axon's Company Presentation before live meetings in the BIO One-on-One Partnering(TM) system begin on June 14.
  • To meet Axon at BIO Digital, you can find registration information here .

Bright Minds Biosciences to Present at the 2021 LD Micro Invitational XI

Wednesday, June 9, 2021 - 9:30pm

The presentation will be webcast live at the aforementioned time and available for 7 days thereafter using the link provided above.

Key Points: 
  • The presentation will be webcast live at the aforementioned time and available for 7 days thereafter using the link provided above.
  • Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain.
  • Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors.
  • Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.

Paul Sinacore Casting LLC Launches Focusing on Diversity, Inclusion as Hollywood Opens Up to Real People

Wednesday, June 9, 2021 - 3:01pm

Studying social psychology, social cognitive neuroscience, brain geography, and fMRI neuroimaging techniques, Paul has applied his knowledge to casting through exploratory research, locating and contacting specific representative samples of target populations and conducting ethnographic interviews.

Key Points: 
  • Studying social psychology, social cognitive neuroscience, brain geography, and fMRI neuroimaging techniques, Paul has applied his knowledge to casting through exploratory research, locating and contacting specific representative samples of target populations and conducting ethnographic interviews.
  • His mission is working with studios and directors to bring real life and multi-cultural human interest stories about marginalized and disenfranchised people to the world, in a fair way.
  • When I was drafted as a first round pick into commercial casting, I struggled with the indifference, lack of integrity, transparency and honesty within the business.
  • with Operation Backlot, a four part series of discussions exploring post Covid-19 mental health issues, sponsored by KCAL and UCLA.

Neuronetics Unveils New Clinical Data at Clinical TMS Society 2021 Annual Meeting

Wednesday, June 9, 2021 - 1:00pm

MALVERN, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced today it will present real-world clinical data as part of the Clinical TMS Society (CTMSS) Annual Meeting.

Key Points: 
  • MALVERN, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced today it will present real-world clinical data as part of the Clinical TMS Society (CTMSS) Annual Meeting.
  • The CTMSS, a professional association that aims to optimize awareness and accessibility of transcranial magnetic stimulation (TMS), will hold its yearly meeting June 10-12 in West Palm Beach, Florida.
  • Its an honor and exciting to present new findings at the Clinical TMS Society Meeting, from theNeuroStar Outcomes Registry, the largest depression registry in the world, said Harold A. Sackeim,PhD, Professor of Clinical Psychology in Psychiatry and Radiology at the College of Physicians and Surgeons, Columbia University, and presenter at the Clinical TMS Society Annual Meeting.
  • Visit the Clinical TMS Societys website to learn more about the annual meeting.

Joanne Garland's new book "A Pink Mountain: Like Mother, Like Son" is an inspirational memoir of a mother and son who both struggle with autism's stigmas and strife

Wednesday, June 9, 2021 - 5:00am

Joanne writes, "I guess it's ironic that a person with such a deep capacity for understanding others, especially those who are the most misunderstood would be so misunderstood herself.

Key Points: 
  • Joanne writes, "I guess it's ironic that a person with such a deep capacity for understanding others, especially those who are the most misunderstood would be so misunderstood herself.
  • But, as it appears to be, in my opinion, most, if not all people with some form of autism, are misunderstood by people who are, shall we say ignorant.
  • Published by Page Publishing, Joanne Garland's inspirational tale dives deeply into her personal struggles with the stigma attached to autism.
  • In her studies, Garland came to a chilling realization, the signals and situations speaking to her, that she too, was on the spectrum.

BrainsWay to Present at the Raymond James Human Health Innovation Conference

Tuesday, June 8, 2021 - 1:00pm

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.

Key Points: 
  • BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.
  • The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives.
  • BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy.
  • Founded in 2003, with offices in Cresskill, NJ and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and broad access to Deep TMS.